Allspring Global Investments Holdings LLC Buys 132,098 Shares of abrdn Life Sciences Investors $HQL

Allspring Global Investments Holdings LLC boosted its position in shares of abrdn Life Sciences Investors (NYSE:HQL) by 57.3% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 362,535 shares of the company’s stock after acquiring an additional 132,098 shares during the period. Allspring Global Investments Holdings LLC’s holdings in abrdn Life Sciences Investors were worth $5,898,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in HQL. Royal Bank of Canada increased its position in shares of abrdn Life Sciences Investors by 53.3% in the 1st quarter. Royal Bank of Canada now owns 73,475 shares of the company’s stock valued at $934,000 after acquiring an additional 25,542 shares during the period. NewEdge Advisors LLC lifted its position in abrdn Life Sciences Investors by 43.1% during the 1st quarter. NewEdge Advisors LLC now owns 32,500 shares of the company’s stock worth $412,000 after acquiring an additional 9,785 shares during the period. First Trust Advisors LP lifted its position in abrdn Life Sciences Investors by 112.2% during the 2nd quarter. First Trust Advisors LP now owns 35,321 shares of the company’s stock worth $452,000 after acquiring an additional 18,674 shares during the period. Raymond James Financial Inc. grew its stake in abrdn Life Sciences Investors by 20.3% during the 2nd quarter. Raymond James Financial Inc. now owns 375,960 shares of the company’s stock valued at $4,816,000 after purchasing an additional 63,429 shares during the last quarter. Finally, Clough Capital Partners L P purchased a new stake in abrdn Life Sciences Investors during the 2nd quarter valued at about $318,000. 32.21% of the stock is currently owned by hedge funds and other institutional investors.

abrdn Life Sciences Investors Price Performance

HQL opened at $19.64 on Friday. abrdn Life Sciences Investors has a 12-month low of $13.01 and a 12-month high of $21.32. The firm has a 50 day moving average of $18.50 and a two-hundred day moving average of $17.53.

abrdn Life Sciences Investors Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Tuesday, June 30th. Investors of record on Thursday, May 21st were issued a dividend of $0.56 per share. This represents a $2.24 annualized dividend and a yield of 11.4%. The ex-dividend date of this dividend was Thursday, May 21st.

About abrdn Life Sciences Investors

abrdn Life Sciences Investors (NYSE: HQL) is a closed-end management investment company that seeks capital appreciation through investment in the life sciences sector. Established in 1994, the trust focuses on equity and equity-related securities of companies engaged in biotechnology, pharmaceuticals, medical devices, diagnostics and related fields. Its closed-end structure allows portfolio managers to maintain a stable pool of capital, pursue long-term investment strategies and employ leverage when deemed appropriate.

The fund’s portfolio spans both public and private companies, with an emphasis on businesses driving innovation in drug development, gene therapy, precision medicine and healthcare technology.